Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 2:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 9,120 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Recurrent Neoplasm Clear all

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: docetaxel, idronoxil, placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Edicotinib, Pharmacokinetic Study; Drug · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Lutetium Lu-177 PNT2002, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy; Drug · Other · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome/Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome/Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Cirtuvivint, Decitabine and Cedazuridine, Echocardiography Test, Multigated Acquisition Scan; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 23
States / cities: New Haven, Connecticut • Atlanta, Georgia • Chicago, Illinois + 17 more

Conditions: High Grade Glioma, Anaplastic Astrocytoma
Interventions: DB107-RRV, DB107-FC; Drug
Lead sponsor: Ashish Shah; Other
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Prolymphocytic Leukemia, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
Interventions: arsenic trioxide, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: New York, New York

Conditions: Endometrial Cancer, Mismatch Repair-Proficient, Recurrent Endometrial Cancer
Interventions: Lenvatinib, Pembrolizumab; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Metastatic Malignant Neoplasm in the Prostate Gland, Prostate Carcinoma, Recurrent Prostate Carcinoma
Interventions: Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography; Procedure · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Brain and Central Nervous System Tumors, Metastatic Cancer
Interventions: iodine I 131 monoclonal antibody 81C6; Radiation
Lead sponsor: Duke University; Other
Eligibility: 3 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Recurrent Thyroid Gland Carcinoma, Stage I Thyroid Gland Papillary Carcinoma, Stage II Thyroid Gland Papillary Carcinoma, Stage III Thyroid Gland Papillary Carcinoma, Stage IV Thyroid Gland Papillary Carcinoma
Interventions: Laboratory Biomarker Analysis, Selumetinib; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 5
States / cities: Tampa, Florida • Chicago, Illinois • Chapel Hill, North Carolina + 2 more

Conditions: Breast Cancer
Interventions: mammography; Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 311
States / cities: Fairbanks, Alaska • Scottsdale, Arizona • Fort Smith, Arkansas + 222 more

Conditions: Adrenocortical Carcinoma
Interventions: MITOTANE; Drug
Lead sponsor: University of Turin, Italy; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 2
States / cities: Bethesda, Maryland • Ann Arbor, Michigan

Conditions: Breast Cancer, Non-Small Cell Lung Cancer, Melanoma, Colorectal Cancer, Pancreatic Cancer, Prostate Adenocarcinoma, Glioma, Primary Solid Tumors
Interventions: 131-I-TM-601 (chlorotoxin); Drug
Lead sponsor: TransMolecular; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 6
States / cities: Birmingham, Alabama • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Recurrent Cervical Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer, Stage III Vaginal Cancer, Stage IIIA Cervical Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Vulvar Cancer, Stage IIIB Cervical Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Vulvar Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Vulvar Cancer, Stage IV Ovarian Epithelial Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer
Interventions: triapine, laboratory biomarker analysis, external beam radiation therapy, brachytherapy, cisplatin, pharmacological study; Drug · Other · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Lung Cancer
Interventions: docetaxel, paclitaxel poliglumex; Drug
Lead sponsor: CTI BioPharma; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 35
States / cities: Hoover, Alabama • Tucson, Arizona • Springdale, Arkansas + 32 more

Conditions: Low-grade Gliomas
Interventions: Tarceva and Rapamycin; Drug
Lead sponsor: Roger Packer; Other
Eligibility: Up to 21 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Prostate Cancer
Interventions: Abiraterone Acetate, Prednisone, Enzalutamide, LHRHa; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: pertuzumab, trastuzumab; Biological
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Depression, Post-traumatic Stress Disorder, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: support group therapy, educational intervention; Procedure · Other
Lead sponsor: Stanford University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Nevada City, California • Stanford, California

Conditions: Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL, Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation), Relapsed/Refractory Mantle Cell Lymphoma (MCL), Relapsed/Refractory Waldenström Macroglobulinemia (WM), Relapsed/Refractory Marginal Zone Lymphoma (MZL), Relapsed/Refractory Follicular Lymphoma (FL)
Interventions: APG-3288; Drug
Lead sponsor: Ascentage Pharma Group Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 5
States / cities: Los Angeles, California • Jacksonville, Florida • Grand Rapids, Michigan + 2 more

Conditions: Leukemia
Interventions: tipifarnib; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Up to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 56
States / cities: Little Rock, Arkansas • Duarte, California • La Jolla, California + 46 more

Conditions: Leukemia
Interventions: cytarabine, daunorubicin hydrochloride, imatinib mesylate; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Prostate Cancer
Interventions: ketoconazole, lenalidomide, therapeutic hydrocortisone; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 6
States / cities: Cleveland, Ohio

Conditions: Lymphoma, Non-Hodgkin
Interventions: Fludarabine, Cyclophosphamide, JCAR017; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 23
States / cities: Santa Monica, California • Aurora, Colorado • New Haven, Connecticut + 18 more

Search by objective public record fields.

Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia

177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia

Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers

Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine

Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole

Efficacy of Adjuvant Mitotane Treatment (ADIUVO)

131-I-TM-601 Study in Adults With Solid Tumors

Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies

Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer

Tarceva/Rapamycin for Children With Low-grade Gliomas With or Without Neurofibromatosis Type 1 (NF1)

Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide

Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab

Phase I: At-Home Support for Rural Women Using Group Video Calling

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

Tipifarnib in Treating Young Patients With Refractory Leukemia

Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia

Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)